<DOC>
	<DOCNO>NCT01467882</DOCNO>
	<brief_summary>The study investigate efficacy , safety pharmacokinetics triptorelin 22.5 mg 6-month formulation 44 patient suffer central precocious puberty . The total study duration per patient 12 month ( 48 week ) .</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetics ( PK ) Triptorelin 6-month Formulation Patients With Central Precocious Puberty</brief_title>
	<detailed_description />
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Inclusion criterion : 1 . Onset development sex characteristic 8 9 year girls boy , respectively ( breast development girl testicular enlargement boy accord Tanner method ) , candidate receive least 12 month GnRH agonist therapy study entry . 2 . Aged 28 year inclusive ( i.e . &lt; 9 year ) girls 29 year inclusive ( i.e . &lt; 10 year ) boys initiation triptorelin treatment . 3 . Initiation triptorelin treatment late 18 month onset first sign precocious puberty . 4 . Difference ( Δ ) bone age ( Greulich Pyle method ) chronological age ≥ 1 year . 5 . Pubertaltype LH response 30 minute follow GnRH agonist stimulation test treatment initiation ( leuprolide acetate 20 μg/kg SC ) ≥ 6 IU/L . 6 . Clinical evidence puberty , define Tanner Staging ≥ 2 breast development girl testicular volume ≥ 4 mL ( cc ) boys . 7 . Informed consent sign one parent parent ( per local requirement ) , liable parent legal guardian ( applicable ) ; assent sign child ≥ 7 year . Noninclusion criterion : 1 . Gonadotropinindependent ( peripheral ) precocious puberty : extra pituitary secretion gonadotropin gonadotropinindependent gonadal adrenal sex steroid secretion . 2 . Nonprogressing isolated premature thelarche . 3 . Presence unstable intracranial tumour intracranial tumour require neurosurgery cerebral irradiation . Patients hamartomas require surgery eligible . 4 . Evidence renal ( creatinine &gt; 2 x ULN ) hepatic impairment ( bilirubin ASAT &gt; 3 x ULN ) . 5 . Any condition chronic illness treatment possibly interfere growth study endpoint ( e.g . chronic steroid use [ except mild topical steroid ] , renal failure , diabetes , moderate severe scoliosis , previously treat intracranial tumour ) . 6 . Prior current therapy GnRH agonist , medroxyprogesterone acetate , growth hormone insulinlike growth factor1 ( IGF 1 ) . 7 . Major medical psychiatric illness could interfere study visit . 8 . Diagnosis short stature , i.e . &gt; 2.25 SD mean height age . 9 . Positive pregnancy test . 10 . Known hypersensibility test material related compound . 11 . Use anticoagulant ( heparin coumarin derivative ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>